Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

US clinical-stage biotech Vigil Neuroscience (Nasdaq: VIGL) today announced a disappointing update on the Phase II IGNITE ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

Sanofi agrees to buy Blueprint Medicines for $9.5 billion, enhancing its rare disease treatments and immunology drug pipeline ...

Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.